There is accumulating evidence that individuals with schizophrenia show altered levels of thyroid hormones. However, a qualitative and quantitative synthesis of findings in this field has not been performed so far. Therefore, we aimed to perform a systematic review and meta-analysis of studies investigating the levels of thyroid-stimulating hormone (TSH), free thyroxine (fT4), total thyroxine (tT4), free triiodothyronine (fT3) and total triiodothyronine (tT3) in multiple-episode schizophrenia (MES) and first-episode psychosis (FEP). Electronic databases were searched from their inception until 30th May 2020 by two independent reviewers. Random-effects meta-analyses and meta-regression analyses were performed. Altogether, 19 studies were included. Persons with FEP had significantly lower TSH levels (5 studies, g = -0.26, 95%CI: -0.47 to -0.06, p = 0.013, I2 = 21.3%), higher fT4 levels (3 studies, g = 0.58, 95%CI: 0.15-1.01, p = 0.008, I2 = 64.6%) and lower tT3 levels (2 studies, g = -0.60, 95%CI: -0.82 to -0.37, p < 0.001, I2 = 0%) compared to controls. Elevated TSH levels were found in persons with MES (13 studies, g = 0.20, 95%CI: 0.02-0.39, p = 0.031, I2 = 50.0%). Our findings imply that the levels of TSH might be decreased in persons with FEP and increased in those with MES. Other alterations need to be confirmed by additional studies. These findings imply the need to monitor the levels of TSH and thyroid hormones from the onset of psychosis.
13 October 2021 in Neuroscience & Biobehavioral Reviews
Digital health interventions (DHIs) show promise for the treatment of mental health disorders. However, existing meta-analytical research is methodologically heterogeneous, with studies including a mix of clinical, non-clinical, and transdiagnostic populations, hindering a comprehensive understanding of DHI effectiveness. Thus, we conducted an umbrella review of meta-analyses of randomised controlled trials investigating the effectiveness of DHIs for specific mental health disorders and evaluating the quality of evidence. We searched three public electronic databases from inception to February, 2024 and included 16 studies. DHIs were effective compared with active interventions for schizophrenia spectrum disorders, major depressive disorder, social anxiety disorder, and panic disorder. Notable treatment effects compared with a waiting list were also observed for specific phobias, generalised anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and bulimia nervosa. Certainty of evidence was rated as very low or low in most cases, except for generalised anxiety disorder-related outcomes, which showed a moderate rating. To integrate DHIs into clinical practice, further high-quality studies with clearly defined target populations and robust comparators are needed.
About Me
MD, Psychiatrist, PhD Student in Neuroscience at the University of Milano-Bicocca, Italy
MD, Psychiatrist, PhD Student in Neuroscience at the University of Milano-Bicocca, Italy